![]() |
|
|
Vol. 288, Issue 3, 1251-1260, March 1999
Human BioMolecular Research Institute, San Diego, California
(J.R.C., Y.N.X., L.X.)
(+)- And (
)-amphetamine and methamphetamine were
N-oxygenated by the cDNA expressed adult human
flavin-containing monooxygenase form 3 (FMO3), their corresponding
hydroxylamines. Two major polymorphic forms of human FMO3 were
studied, and the results suggested preferential N-oxygenation by only one of the two enzymes. Chemically
synthesized (±)-amphetamine hydroxylamine was also a substrate for the
human FMO3 and it was converted to phenylpropanone oxime with a
stereoselectivity ratio of trans/cis of 5:1. Human FMO3
also N-oxygenated methamphetamine to produce
methamphetamine hydroxylamine. Methamphetamine hydroxylamine was also
N-oxygenated by human FMO3, and the ultimate product observed was phenylpropanone. For amphetamine hydroxylamine, studies of
the biochemical mechanism of product formation were consistent with the
production of an N,N-dioxygenated intermediate that lead to phenylpropanone oxime. This was supported by the observation that
-deutero (±)-amphetamine hydroxylamine gave an inverse kinetic isotope effect on product formation in the presence of human FMO3. For
methamphetamine, the data were consistent with a mechanism of human
FMO3-mediated N,N-dioxygenation but the immediate
product, a nitrone, rapidly hydrolyzed to phenylpropanone. The
pharmacological activity of amphetamine hydroxylamine, phenylpropanone
oxime, and methamphetamine hydroxylamine were examined for effects at the human dopamine, serotonin, and norepinephrine transporters. Amphetamine hydroxylamine and methamphetamine hydroxylamine were apparent substrates for the human biogenic amine transporters but
phenylpropanone oxime was not. Presumably, phenylpropanone oxime or
nitrone formation from amphetamine and methamphetamine, respectively,
represents a detoxication process. Because of the potential toxic
nature of amphetamine hydroxylamine and methamphetamine hydroxylamine
metabolites and the polymorphic nature of N-oxygenation, human FMO3-mediated metabolism of amphetamine or methamphetamine may
have clinical consequences.
This article has been cited by other articles:
![]() |
P. M. Vyas, S. Roychowdhury, and C. K. Svensson ROLE OF HUMAN CYCLOOXYGENASE-2 IN THE BIOACTIVATION OF DAPSONE AND SULFAMETHOXAZOLE Drug Metab. Dispos., January 1, 2006; 34(1): 16 - 18. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. R. Cashman and J. Zhang Interindividual Differences of Human Flavin-Containing Monooxygenase 3: Genetic Polymorphisms and Functional Variation Drug Metab. Dispos., October 1, 2002; 30(10): 1043 - 1052. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. K. Yeung, D. H. Lang, K. E. Thummel, and A. E. Rettie Immunoquantitation of FMO1 in Human Liver, Kidney, and Intestine Drug Metab. Dispos., September 1, 2000; 28(9): 1107 - 1111. [Abstract] [Full Text] |
||||
![]() |
A S KASHYAP and S. KASHYAP Fish odour syndrome Postgrad. Med. J., May 1, 2000; 76(895): 318a - 318. [Full Text] |
||||